Investor Alert: Pomerantz Law Firm Investigates Claims Against ACADIA Pharmaceuticals Inc.
Pomerantz LLP is investigating potential securities fraud or other unlawful business practices by ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) and certain of its officers and directors on behalf of investors. The investigation follows the company's announcement in late September 2026 that remlifanserin, a drug candidate for Alzheimer’s disease psychosis, narrowly missed meeting its primary endpoint during Phase 3 trials. This news led to an immediate drop in Acadia's stock price by $3.25 per share (12.78%) on September 24 and further declined another $1.50 per share (6.76%) the following day after multiple analysts downgraded the company due to disappointing results. Pomerantz LLP, a well-known firm in securities litigation, is inviting investors who may have been affected by these developments to contact them for potential class action participation.
Tickers: $ACAD
Topics: clinical trial results legal action stock price drop